Similar Papers

Paper Title
Journal
Date
Author
FLASH Modulation of Immune Microenvironment in Diffuse Midline Glioma (DMG) at Single-Cell Resolution
...
International Journal of Radiation Oncology*Biology*Physics | VOL. 114
, et. al. ...
01 Nov 2022
Limited effects of β-endorphin compared to loperamide or fentanyl in a neuroendocrine biomarker assay in non-human primates
Eduardo R Butelman ... Mary Jeanne Kreek
Psychoneuroendocrinology | VOL. 33
Eduardo R Butelman, et. al.Eduardo R Butelman ... Mary Jeanne Kreek
02 Jan 2008
Transfection of IFNalpha in human glioblastoma cells and tumorigenicity in association with induction of PKR and OAS gene expression.
Ju He ... C David James
Journal of neurosurgery | VOL. 85
Ju He, et. al.Ju He ... C David James
01 Dec 1996
Toll-Like Receptor 4 or 2 Agonists Decrease Allergic Inflammation
German Velasco ... Ruth S S Arestides
American Journal of Respiratory Cell and Molecular Biology | VOL. 32
German Velasco, et. al.German Velasco ... Ruth S S Arestides
02 Dec 2004
View more papers

More From: Cancers

Paper Title
Journal
Date
Author
DNA Repair Capacity and Clinicopathological Characteristics in Puerto Rican Hispanic/Latino Patients with Metastatic Castration-Resistant Prostate Cancer
Jaime Matta ... Gilberto Ruiz-Deya
Cancers | VOL. 17
Jaime Matta, et. al.Jaime Matta ... Gilberto Ruiz-Deya
16 Jan 2025
Phase II Study of Atezolizumab and Bevacizumab Combination Therapy for Patients with Advanced Hepatocellular Carcinoma Previously Treated with Lenvatinib
Takeshi Terashima ... Taro Yamashita
Cancers | VOL. 17
Takeshi Terashima, et. al.Takeshi Terashima ... Taro Yamashita
16 Jan 2025
Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia
Erhan Aptullahoglu ... John Lunec
Cancers | VOL. 17
Erhan Aptullahoglu, et. al.Erhan Aptullahoglu ... John Lunec
16 Jan 2025
A Novel Nomogram for Estimating a High-Risk Result in the EndoPredict® Test for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Carcinoma
Víctor Macarrón ... David Hardisson
Cancers | VOL. 17
Víctor Macarrón, et. al.Víctor Macarrón ... David Hardisson
16 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.